Joshua D Lee
Joshua D. Lee, MD, MSc
NYU Langone Health - Professor, Department of Population Health, Division of General Medicine and Clinical Innovation
MD, University of Tennessee College of Medicine
MSc, Weill Cornell Graduate School of Medical Sciences
AB, Art and Archeology, Princeton University
Research Interests
Addiction pharmacotherapies, Primary care, Criminal justice
Joshua D. Lee is a Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at NYU Langone Health. He is a clinician researcher focused on addiction pharmacotherapies, and is Director of the NYU ABAM Fellowship in Addiction Medicine. His research models the use of addiction pharmacotherapies in primary care and criminal justice populations. He has conducted multiple NIH and other clinical trials examining the use of extended-release naltrexone and buprenorphine opioid treatments in outpatient criminal justice involved-adults, in soon-to-be released jail inmates, and in community detox settings. Research on extended-release naltrexone for alcohol treatment has focused on primary care medical management. Dr. Lee graduated Princeton University (AB), the University of Tennessee School of Medicine (MD), and Weill Cornell Graduate School of Medical Sciences (MSc). He completed a residency and chief residency in Primary Care Internal Medicine at NYU/Bellevue Hospital Center and is certified in Addiction Medicine. He is currently an attending physician at Bellevue Hospital and in the New York City jails.
Principal Investigator, Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017. Active
Principal Investigator, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-Involved Adults. Active
Principal Investigator, Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-Entry. Completed
Principal Investigator, Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care. Completed


Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR (2024).
Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
Addiction, 119 (7), 1313-1321. doi: 10.1111/add.16473. PMCID: PMC11156545.

Cherian T, Lim S, Katyal M, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Rosner Z, MacDonald R, Lee JD (2024).
Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration
Drug and Alcohol Dependence, 259, 111274. doi: 10.1016/j.drugalcdep.2024.111274.

Tofighi B, Lopez R, Araujo G, Lee JD, Samuels EA, Wightman RS, Butner J (2024).
Provider and administrator attitudes and experiences with implementing telebuprenorphine during the COVID-19 pandemic: A mixed-methods survey
Journal of Substance Use, 29 (3), 347-353. doi: 10.1080/14659891.2023.2166609.

Lim S, Cherian T, Katyal M, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Rosner Z, MacDonald R, Lee JD (2024).
Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis
Journal of Substance Use and Addiction Treatment, 158, 209254. doi: 10.1016/j.josat.2023.209254. PMCID: PMC10947890.

Shulman M, Choo TH, Scodes J, Pavlicova M, Novo P, Campbell ANC, Greiner M, Lee JD, Rotrosen J, Nunes EV (2023).
Secondary analysis of agreement between negative timeline follow back report and negative urine toxicology in a large trial of individuals with opioid use disorder
Journal of Addiction Medicine, 17 (5), 618-620. doi: 10.1097/ADM.0000000000001173. PMCID: PMC10593984.


Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP (2016).
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
New England Journal of Medicine, 374 (13), 1232-1242. doi: 10.1056/NEJMoa1505409. PMCID: PMC5454800.

Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN (2015).
Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial
Addiction, 110 (6), 1008-1014. doi: 10.1111/add.12894.

Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch M (2012).
Buprenorphine-naloxone maintenance following release from jail
Substance Abuse, 33 (1), 40-47. doi: 10.1080/08897077.2011.620475. PMCID: PMC3310898.

Dr. Lee's MyBibliography Profile
Selected Press